clofazimine has been researched along with Infection, Mycobacterium avium-intracellulare in 62 studies
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "During a randomized study of clarithromycin plus clofazimine with or without ethambutol in patients with AIDS and Mycobacterium avium complex (MAC) bacteremia, eight participants received additional antimycobacterial drugs following the detection of a clarithromycin-resistant isolate (MIC, > 8 micrograms/mL)." | 9.09 | Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group. ( Dubé, MP; Havlir, DV; Kemper, CA; Leedom, JM; McCutchan, JA; Sattler, FR; See, D; Tilles, JG; Torriani, FJ, 1999) |
| " avium complex bacteremia to receive either rifampin (600 mg daily), ethambutol (approximately 15 mg per kilogram of body weight daily), clofazimine (100 mg daily), and ciprofloxacin (750 mg twice daily) (the four-drug group) or rifabutin (600 mg daily), ethambutol (as above), and clarithromycin (1000 mg twice daily) (the three-drug group)." | 9.08 | A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. ( Fanning, MM; Fong, IW; Gill, MJ; Lalonde, RG; Phillips, P; Rachlis, AR; Salit, I; Shafran, SD; Singer, J; Tsoukas, CM; Walmsley, SL; Zarowny, DP, 1996) |
| "The individual antibacterial activities of clofazimine, ethambutol, and rifampin in the treatment of Mycobacterium avium complex bacteremia in patients with AIDS were determined." | 9.07 | The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS. ( Bartok, AE; Dubé, M; Haghighat, D; Havlir, D; Kemper, CA; Leedom, JM; Sison, JP; Tilles, JG; Yangco, B; Yao, Y, 1994) |
| "A rapid reduction in symptoms and bacteremia can be achieved as early as week 2 of therapy using an oral regimen of rifampin, ethambutol, clofazimine, and ciprofloxacin." | 9.07 | Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Rifampin, ethambutol, clofazimine, and ciprofloxacin. The California Collaborative Treatment Group. ( Bartok, AE; Chiu, J; Deresinski, SC; Feigal, DF; Kemper, CA; Leedom, JM; McCutchan, JA; Meng, TC; Nussbaum, J; Tilles, JG, 1992) |
| "This article reviews the chemistry, pharmacology, spectrum of activity, pharmacokinetics, clinical efficacy in leprosy and Mycobacterium avium complex (MAC) infection, adverse effects, drug interactions, and special considerations of clofazimine." | 8.78 | Clofazimine: a review of its use in leprosy and Mycobacterium avium complex infection. ( Garrelts, JC, 1991) |
| "We describe four additional AIDS patients with MAC disease who had a favorable clinical and microbiological response to this regimen without developing serious adverse effects after periods ranging from 4 to 12 months." | 5.28 | Successful treatment of acquired immunodeficiency syndrome-related Mycobacterium avium complex disease with a multiple drug regimen including amikacin. ( Benson, CA; Kessler, HA; Pottage, JC; Trenholme, GM, 1991) |
| "During a randomized study of clarithromycin plus clofazimine with or without ethambutol in patients with AIDS and Mycobacterium avium complex (MAC) bacteremia, eight participants received additional antimycobacterial drugs following the detection of a clarithromycin-resistant isolate (MIC, > 8 micrograms/mL)." | 5.09 | Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group. ( Dubé, MP; Havlir, DV; Kemper, CA; Leedom, JM; McCutchan, JA; Sattler, FR; See, D; Tilles, JG; Torriani, FJ, 1999) |
| " avium complex bacteremia to receive either rifampin (600 mg daily), ethambutol (approximately 15 mg per kilogram of body weight daily), clofazimine (100 mg daily), and ciprofloxacin (750 mg twice daily) (the four-drug group) or rifabutin (600 mg daily), ethambutol (as above), and clarithromycin (1000 mg twice daily) (the three-drug group)." | 5.08 | A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. ( Fanning, MM; Fong, IW; Gill, MJ; Lalonde, RG; Phillips, P; Rachlis, AR; Salit, I; Shafran, SD; Singer, J; Tsoukas, CM; Walmsley, SL; Zarowny, DP, 1996) |
| "We conducted a randomized, open-label trial in 42 French hospitals to compare the clinical and bacteriologic efficacy of combination therapy with clarithromycin/clofazimine (Clm/Clof) with that of combination therapy with clarithromycin/rifabutin/ethambutol (Clm/Rib/Eth) as treatment for Mycobacterium avium bacteremia." | 5.08 | Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 Curavium Group. Agence Nationale de Recherche sur le Sida. ( Beuscart, C; Brel, F; Dautzenberg, B; Doco-Lecompte, T; Grosset, J; May, T; Perronne, C; Saint-Marc, T; Vincent, V, 1997) |
| " a placebo, each in combination with clofazimine and ethambutol, for the treatment of MAC bacteremia." | 5.07 | Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex. The Rifabutin Treatment Group. ( Gordin, FM; Sullam, PM; Wynne, BA, 1994) |
| "The individual antibacterial activities of clofazimine, ethambutol, and rifampin in the treatment of Mycobacterium avium complex bacteremia in patients with AIDS were determined." | 5.07 | The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS. ( Bartok, AE; Dubé, M; Haghighat, D; Havlir, D; Kemper, CA; Leedom, JM; Sison, JP; Tilles, JG; Yangco, B; Yao, Y, 1994) |
| "A rapid reduction in symptoms and bacteremia can be achieved as early as week 2 of therapy using an oral regimen of rifampin, ethambutol, clofazimine, and ciprofloxacin." | 5.07 | Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Rifampin, ethambutol, clofazimine, and ciprofloxacin. The California Collaborative Treatment Group. ( Bartok, AE; Chiu, J; Deresinski, SC; Feigal, DF; Kemper, CA; Leedom, JM; McCutchan, JA; Meng, TC; Nussbaum, J; Tilles, JG, 1992) |
| "This article reviews the chemistry, pharmacology, spectrum of activity, pharmacokinetics, clinical efficacy in leprosy and Mycobacterium avium complex (MAC) infection, adverse effects, drug interactions, and special considerations of clofazimine." | 4.78 | Clofazimine: a review of its use in leprosy and Mycobacterium avium complex infection. ( Garrelts, JC, 1991) |
| " The following areas were emphasized at the conference: multiresistant gram-positive bacteremias in patients with serious underlying infections, azithromycin's effectiveness against acute community-acquired pneumonia, results of clarithromycin plus ethambutol in HIV-infected patients with MAC bacteremia, duodenal ulcers associated with Helicobacter pylori infections, and use of roxithromycin against AIDS-related cryptosporidium diarrhea." | 3.69 | Macrolides, azalides, and streptogrammins. ( Prescott, LM, 1996) |
| " Results of a Taiwanese trial of thymosin-alpha indicate that it did not help treat Hepatitis B in a statistically significant way." | 3.69 | Pot shots. ( , 1996) |
| " Tolerance to the drugs was generally good, apart from three cases of hepatic disturbances and three cases of ototoxicity, which required a decrease in clarithromycin dosage after a short interruption of treatment." | 2.69 | Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections à Mycobactéries. ( Igual, J; Roussel, G, 1998) |
| "Amikacin was well tolerated." | 2.69 | A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated Mycobacterium avium infection in HIV-infected individuals. AIDS Clinical Trials Group Protocol 135 Study Team. ( Barber, TW; Currier, J; Ellner, JJ; Hafner, R; Hojczyk, P; Hooton, TM; Jacobs, MR; Limjoco, M; Parenti, DM; Powderly, WG; Simpson, G; van der Horst, C; Williams, PL, 1998) |
| " The Data and Safety Monitoring Board recommended discontinuation of the clarithromycin dosage comparison and continuation of the rifabutin vs." | 2.69 | A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Terry Beirn Community Programs for Clinical Resear ( Chesnut, J; Child, CC; Clotfelter, J; Cohn, DL; El-Sadr, W; Fisher, EJ; Franchino, B; Gibert, CL; Hafner, R; Heifets, L; Hodges, JS; Horsburgh, CR; Korvick, J; Munroe, D; Peng, GT; Ropka, M, 1999) |
| "Clofazimine was discontinued because of gastrointestinal intolerance in 1 of the 5 patients." | 1.42 | Safety and tolerability of clofazimine as salvage therapy for atypical mycobacterial infection in solid organ transplant recipients. ( Abdel-Massih, RC; Cariello, PF; Kwak, EJ; Silveira, FP, 2015) |
| "We have studied the bioavailability of clofazimine following administration of a single dose of the drug in the biodegradable polymer polylactic-co-glycolic acid (PLGA)." | 1.29 | Bioavailability and chemotherapeutic activity of clofazimine against Mycobacterium avium complex infections in beige mice following a single implant of a biodegradable polymer. ( Gangadharam, PR; Kailasam, S; Wise, DL, 1994) |
| "Clofazimine was chosen for further studies because it could be effectively encapsulated and its activity was well maintained in liposomal form." | 1.29 | Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection. ( Mehta, RT, 1996) |
| "We studied patients with AIDS and DMAC and compared their survival with that of AIDS patients without DMAC but with other comparable risk factors for survival." | 1.28 | Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy. ( Dubois, RE; Ellis, DA; Fann, SA; Havlik, JA; Horsburgh, CR; Kennedy, E; Thompson, SE, 1991) |
| "We describe four additional AIDS patients with MAC disease who had a favorable clinical and microbiological response to this regimen without developing serious adverse effects after periods ranging from 4 to 12 months." | 1.28 | Successful treatment of acquired immunodeficiency syndrome-related Mycobacterium avium complex disease with a multiple drug regimen including amikacin. ( Benson, CA; Kessler, HA; Pottage, JC; Trenholme, GM, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (4.84) | 18.7374 |
| 1990's | 48 (77.42) | 18.2507 |
| 2000's | 3 (4.84) | 29.6817 |
| 2010's | 5 (8.06) | 24.3611 |
| 2020's | 3 (4.84) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, S | 1 |
| Hua, W | 1 |
| Wang, S | 1 |
| Zhang, Y | 1 |
| Chen, X | 1 |
| Liu, H | 1 |
| Shao, L | 1 |
| Chen, J | 1 |
| Zhang, W | 1 |
| Park, YE | 1 |
| Chong, YP | 1 |
| Lee, HJ | 1 |
| Shim, TS | 2 |
| Jo, KW | 2 |
| Hajikhani, B | 1 |
| Nasiri, MJ | 1 |
| Hosseini, SS | 1 |
| Khalili, F | 1 |
| Karimi-Yazdi, M | 1 |
| Hematian, A | 1 |
| Nojookambari, NY | 1 |
| Goudarzi, M | 1 |
| Dadashi, M | 1 |
| Mirsaeidi, M | 1 |
| Huang, CC | 1 |
| Wu, MF | 1 |
| Chen, HC | 1 |
| Huang, WC | 1 |
| Uthman, MM | 1 |
| Uthman, OA | 1 |
| Yahaya, I | 1 |
| Kim, S | 1 |
| Lee, JY | 1 |
| Lee, SD | 1 |
| Kim, WS | 1 |
| Kim, DS | 1 |
| Cariello, PF | 1 |
| Kwak, EJ | 1 |
| Abdel-Massih, RC | 1 |
| Silveira, FP | 1 |
| Jarand, J | 1 |
| Davis, JP | 1 |
| Cowie, RL | 2 |
| Field, SK | 2 |
| Fisher, DA | 1 |
| Saito, H | 2 |
| Tomioka, H | 1 |
| Sato, K | 2 |
| Kawahara, S | 1 |
| Hidaka, T | 1 |
| Dekio, S | 1 |
| Reddy, MV | 1 |
| Srinivasan, S | 1 |
| Gangadharam, PR | 4 |
| Sullam, PM | 1 |
| Gordin, FM | 1 |
| Wynne, BA | 1 |
| Olliaro, P | 1 |
| Dautzenberg, B | 3 |
| Steven, N | 1 |
| Pithie, A | 1 |
| Wood, M | 1 |
| Innes, J | 1 |
| Kemper, CA | 6 |
| Havlir, D | 2 |
| Haghighat, D | 1 |
| Dubé, M | 1 |
| Bartok, AE | 3 |
| Sison, JP | 3 |
| Yao, Y | 3 |
| Yangco, B | 1 |
| Leedom, JM | 3 |
| Tilles, JG | 3 |
| Kane, C | 1 |
| Camp, B | 1 |
| Lane, N | 1 |
| Deresinski, SC | 4 |
| Saint-Marc, T | 3 |
| Durant, J | 1 |
| Reynes, J | 1 |
| Meyohas, MC | 1 |
| Legrand, MF | 1 |
| Truffot, C | 1 |
| Chauvin, JP | 1 |
| Marneff, E | 1 |
| Touraine, JL | 1 |
| Kailasam, S | 1 |
| Wise, DL | 1 |
| Gordon, SM | 1 |
| Horsburgh, CR | 3 |
| Peloquin, CA | 2 |
| Havlik, JA | 2 |
| Metchock, B | 1 |
| Heifets, L | 2 |
| McGowan, JE | 1 |
| Thompson, SE | 2 |
| Silverman, JF | 1 |
| Holter, JF | 1 |
| Berns, LA | 1 |
| Benning, TL | 1 |
| Neill, JS | 1 |
| Soriano, V | 1 |
| Moreno, V | 1 |
| Alba, A | 1 |
| Laguna, F | 1 |
| González-Lahoz, J | 1 |
| Abrams, DI | 1 |
| Mitchell, TF | 1 |
| Child, CC | 2 |
| Shiboski, SC | 1 |
| Brosgart, CL | 1 |
| Mass, MM | 1 |
| Hamilton, JR | 2 |
| Brummer, E | 2 |
| Stevens, DA | 2 |
| Shafran, SD | 2 |
| Singer, J | 2 |
| Zarowny, DP | 1 |
| Phillips, P | 1 |
| Salit, I | 2 |
| Walmsley, SL | 1 |
| Fong, IW | 1 |
| Gill, MJ | 1 |
| Rachlis, AR | 1 |
| Lalonde, RG | 1 |
| Fanning, MM | 1 |
| Tsoukas, CM | 2 |
| Fattorini, L | 1 |
| Vincent, V | 3 |
| Li, B | 1 |
| Xiao, Y | 1 |
| Varnerot, A | 1 |
| Tortoli, E | 1 |
| Piersimoni, C | 1 |
| Mandler, F | 1 |
| Mascellino, MT | 1 |
| Iona, E | 1 |
| Orefici, G | 1 |
| Mehta, RT | 3 |
| Brown-Harrell, V | 1 |
| Nitta, AT | 1 |
| Goble, M | 1 |
| Fisher, M | 1 |
| Tomlinson, DR | 1 |
| Coker, RJ | 1 |
| Kansal, RG | 1 |
| Gomez-Flores, R | 2 |
| Sinha, I | 1 |
| Tucker, SD | 1 |
| Kansal, R | 1 |
| Tamez-Guerra, R | 1 |
| Chaisson, RE | 1 |
| Keiser, P | 1 |
| Pierce, M | 1 |
| Fessel, WJ | 1 |
| Ruskin, J | 1 |
| Lahart, C | 1 |
| Benson, CA | 2 |
| Meek, K | 1 |
| Siepman, N | 1 |
| Craft, JC | 1 |
| May, T | 1 |
| Brel, F | 1 |
| Beuscart, C | 1 |
| Perronne, C | 1 |
| Doco-Lecompte, T | 1 |
| Grosset, J | 1 |
| Alfandari, S | 1 |
| Chidiac, C | 1 |
| Guery, B | 1 |
| Senneville, E | 1 |
| Mouton, Y | 1 |
| Vinocour, D | 1 |
| Faris, MA | 1 |
| Raasch, RH | 1 |
| Hopfer, RL | 1 |
| Butts, JD | 1 |
| Roussel, G | 1 |
| Igual, J | 1 |
| Parenti, DM | 1 |
| Williams, PL | 1 |
| Hafner, R | 2 |
| Jacobs, MR | 1 |
| Hojczyk, P | 1 |
| Hooton, TM | 1 |
| Barber, TW | 1 |
| Simpson, G | 1 |
| van der Horst, C | 1 |
| Currier, J | 2 |
| Powderly, WG | 1 |
| Limjoco, M | 1 |
| Ellner, JJ | 1 |
| Dubé, MP | 1 |
| Torriani, FJ | 1 |
| See, D | 1 |
| Havlir, DV | 1 |
| McCutchan, JA | 2 |
| Sattler, FR | 1 |
| Harbeck, RJ | 1 |
| Worthen, GS | 1 |
| Lebo, TD | 1 |
| Fournier, S | 1 |
| Burguière, AM | 1 |
| Flahault, A | 1 |
| Treilhou, MP | 1 |
| Eliaszewicz, M | 1 |
| Cohn, DL | 1 |
| Fisher, EJ | 1 |
| Peng, GT | 1 |
| Hodges, JS | 1 |
| Chesnut, J | 1 |
| Franchino, B | 1 |
| Gibert, CL | 1 |
| El-Sadr, W | 2 |
| Korvick, J | 1 |
| Ropka, M | 1 |
| Clotfelter, J | 1 |
| Munroe, D | 1 |
| Peters, K | 1 |
| Leitzke, S | 1 |
| Diederichs, JE | 1 |
| Borner, K | 1 |
| Hahn, H | 1 |
| Müller, RH | 1 |
| Ehlers, S | 1 |
| Thorne, A | 1 |
| Khorasheh, S | 1 |
| Raboud, JM | 1 |
| Wu, AW | 1 |
| Lemieux, C | 1 |
| Cheng, B | 1 |
| Prescott, LM | 1 |
| Parikh, K | 1 |
| Ashtekar, D | 1 |
| O'Sullivan, JF | 1 |
| Meng, TC | 1 |
| Nussbaum, J | 1 |
| Chiu, J | 1 |
| Feigal, DF | 1 |
| Ellis, DA | 1 |
| Kennedy, E | 1 |
| Fann, SA | 1 |
| Dubois, RE | 1 |
| Kessler, HA | 1 |
| Pottage, JC | 1 |
| Trenholme, GM | 1 |
| Garrelts, JC | 1 |
| Hoy, J | 1 |
| Mijch, A | 1 |
| Sandland, M | 1 |
| Grayson, L | 1 |
| Lucas, R | 1 |
| Dwyer, B | 1 |
| O'Brien, RJ | 1 |
| Geiter, LJ | 1 |
| Lyle, MA | 1 |
| Cunningham, CA | 1 |
| Friedberg, DN | 1 |
| Carr, RE | 1 |
| Agins, BD | 1 |
| Berman, DS | 1 |
| Spicehandler, D | 1 |
| Simberkoff, MS | 1 |
| Rahal, JJ | 1 |
| Hudson, V | 1 |
| Cox, F | 1 |
| Taylor, L | 1 |
| Guill, M | 1 |
| Wray, B | 1 |
| Steele, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease[NCT00002058] | 0 participants | Interventional | Completed | ||||
| Magnetic Resonance Imaging to Study Avascular Necrosis in HIV-Infected Subjects[NCT00001762] | 532 participants (Actual) | Observational | 1998-02-23 | Completed | |||
| Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex Infection[NCT00001763] | Phase 1 | 15 participants | Interventional | 1998-04-30 | Completed | ||
| A Randomized Open-Label Study of the Tolerability and Efficacy of Clarithromycin and Ethambutol in Combination With or Without Clofazimine for the Treatment of Disseminated MAC (dMAC) in Patients With AIDS[NCT00002331] | 0 participants | Interventional | 1994-01-31 | Completed | |||
| A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.[NCT00000641] | Phase 2 | 90 participants | Interventional | Completed | |||
| An Open-Label, Randomized Trial of Four Treatment Regimens for Patients With Disseminated Mycobacterium Avium Complex Disease and Acquired Immunodeficiency Syndrome (AIDS)[NCT00001047] | Phase 3 | 400 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for clofazimine and Infection, Mycobacterium avium-intracellulare
| Article | Year |
|---|---|
Clofazimine susceptibility testing of Mycobacterium avium complex and Mycobacterium abscessus: a meta-analysis study.
Topics: Clofazimine; Humans; Microbial Sensitivity Tests; Mycobacterium abscessus; Mycobacterium avium Compl | 2021 |
Interventions for the prevention of mycobacterium avium complex in adults and children with HIV.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Azithromycin; Child; Clarithrom | 2013 |
Treatment and prophylaxis of disseminated Mycobacterium avium complex in HIV-infected individuals.
Topics: 4-Quinolones; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antibiotic Prophylaxis; | 1998 |
Clofazimine: a review of its use in leprosy and Mycobacterium avium complex infection.
Topics: Acquired Immunodeficiency Syndrome; Clofazimine; Drug Interactions; Gastrointestinal Diseases; Human | 1991 |
21 trials available for clofazimine and Infection, Mycobacterium avium-intracellulare
| Article | Year |
|---|---|
Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex. The Rifabutin Treatment Group.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Bacteremia; Clofazimine; | 1994 |
Control of the body burden of M. avium complex is associated with improved quality of life and prolonged survival of patients with AIDS: a prospective trial with rifabutin combined with isoniazid, clofazimine, ethambutol.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Body Burden; Clofazimine; Drug Therapy, Combinat | 1994 |
The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Bacteremia; Clofazimine; Ethambutol; Femal | 1994 |
Transient bacteremia due to Mycobacterium avium complex in patients with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Bacteremia; Clofazimine; Drug Therapy, Combination; Et | 1994 |
[Treatment with clarithromycin of 173 HIV+ patients with disseminated Mycobacterium avium intracellulare infection].
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antitubercular Agen | 1994 |
[Mycobacterium avium intracellulare infections. Treatment with a clarithromycin-clofazimine combination. 18 cases].
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Chemical and Drug | 1993 |
Clofazimine as prophylaxis for disseminated Mycobacterium avium complex infection in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Clofazimine; Female; Humans; Male; Middle Aged; Mycobacte | 1993 |
Treatment of Mycobacterium avium complex infection: do the results of in vitro susceptibility tests predict therapeutic outcome in humans?
Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antitubercular Agents; Bacteremi | 1996 |
Treatment of Myocardium avium complex infection: does the beige mouse model predict therapeutic outcome in humans?
Topics: AIDS-Related Opportunistic Infections; Animals; Antitubercular Agents; Clofazimine; Colony Count, Mi | 1996 |
A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Bacterem | 1996 |
Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Clarithr | 1997 |
Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Clarithr | 1997 |
Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Clarithr | 1997 |
Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Clarithr | 1997 |
Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Clarithr | 1997 |
Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Clarithr | 1997 |
Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Clarithr | 1997 |
Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Clarithr | 1997 |
Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Clarithr | 1997 |
Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 Curavium Group. Agence Nationale de Recherche sur le Sida.
Topics: Adult; AIDS-Related Opportunistic Infections; Bacteremia; Clarithromycin; Clofazimine; Drug Therapy, | 1997 |
Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections à Mycobactéries.
Topics: Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Clofazimine; Drug Administration Schedule; Drug | 1998 |
A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated Mycobacterium avium infection in HIV-infected individuals. AIDS Clinical Trials Group Protocol 135 Study Team.
Topics: Adult; AIDS-Related Opportunistic Infections; Amikacin; Bacteremia; Ciprofloxacin; Clofazimine; Colo | 1998 |
Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group.
Topics: AIDS-Related Opportunistic Infections; Bacteremia; Ciprofloxacin; Clarithromycin; Clofazimine; Drug | 1999 |
Effect of adding clofazimine to combined clarithromycin-ethambutol therapy for Mycobacterium avium complex septicemia in AIDS patients.
Topics: Aged; AIDS-Related Opportunistic Infections; Anti-Inflammatory Agents, Non-Steroidal; Bacteremia; Cl | 1999 |
A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Terry Beirn Community Programs for Clinical Resear
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antibiotics, Antitubercular; Cl | 1999 |
Symptomatic and health status outcomes in the Canadian randomized MAC treatment trial (CTN010). Canadian HIV Trials Network Protocol 010 Study Group.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Bacteremia; Canada; | 2000 |
New antibiotics look good against M. avium.
Topics: Acquired Immunodeficiency Syndrome; Azithromycin; Clarithromycin; Clofazimine; Drug Therapy, Combina | 1992 |
Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Rifampin, ethambutol, clofazimine, and ciprofloxacin. The California Collaborative Treatment Group.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Amikacin; Anti-Infective Agents; Ba | 1992 |
Rifabutin (ansamycin LM427) for the treatment of pulmonary Mycobacterium avium complex.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antitubercular Agents; Clofazimine; Cyclose | 1990 |
37 other studies available for clofazimine and Infection, Mycobacterium avium-intracellulare
| Article | Year |
|---|---|
In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Clofazimine; Humans; M | 2022 |
Clinical Outcome with Standard Regimen plus Clofazimine or Moxifloxacin in Cavitary Mycobacterium avium Complex Pulmonary Disease.
Topics: Anti-Bacterial Agents; Clofazimine; Humans; Lung Diseases; Moxifloxacin; Mycobacterium avium Complex | 2022 |
In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates.
Topics: Aminoglycosides; Anti-Bacterial Agents; Clarithromycin; Clofazimine; Cycloserine; Drug Synergism; Fl | 2018 |
Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacy.
Topics: Aged; Anti-Bacterial Agents; Clofazimine; Drug Therapy, Combination; Female; Fluoroquinolones; Human | 2014 |
Safety and tolerability of clofazimine as salvage therapy for atypical mycobacterial infection in solid organ transplant recipients.
Topics: Adult; Aged; Clofazimine; Female; Humans; Leprostatic Agents; Male; Middle Aged; Mycobacterium avium | 2015 |
Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clofazimine; Drug Therapy, Combination; Etham | 2016 |
Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine.
Topics: Aged; Aged, 80 and over; Antitubercular Agents; Clofazimine; Drug Therapy, Combination; Ethambutol; | 2003 |
Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice.
Topics: Animals; Antitubercular Agents; Clarithromycin; Clofazimine; Drug Synergism; Drug Therapy, Combinati | 1995 |
In vitro and in vivo synergistic effect of isoniazid with streptomycin and clofazimine against Mycobacterium avium complex (MAC).
Topics: AIDS-Related Opportunistic Infections; Animals; Clofazimine; Colony Count, Microbial; Dose-Response | 1994 |
Corticosteroid therapy for AIDS patients with Mycobacterium avium-intracellulare infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Azithromycin; Ciprofloxacin; Clofazimine; Drug Therapy | 1994 |
Bioavailability and chemotherapeutic activity of clofazimine against Mycobacterium avium complex infections in beige mice following a single implant of a biodegradable polymer.
Topics: Animals; Biological Availability; Clofazimine; Drug Implants; Lactic Acid; Liver; Male; Mice; Mice, | 1994 |
Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease.
Topics: Administration, Oral; Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agent | 1993 |
Negative images due to clofazimine crystals simulating MAI infection in a bronchoalveolar lavage specimen.
Topics: Adult; AIDS-Related Opportunistic Infections; Bronchoalveolar Lavage Fluid; Clofazimine; Crystalliza | 1993 |
Kussmaul respiration and abdominal pain secondary to metabolic acidosis in AIDS patients with disseminated Mycobacterium avium complex infection receiving clofazimine.
Topics: Abdominal Pain; Acidosis; Acquired Immunodeficiency Syndrome; Clofazimine; Humans; Male; Mycobacteri | 1993 |
Type frequency and antimicrobial susceptibility of Mycobacterium avium-intracellulare complex strains isolated in Italy from AIDS and non-AIDS patients.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infective Agen | 1996 |
Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection.
Topics: Animals; Anti-Bacterial Agents; Cells, Cultured; Clofazimine; Disease Models, Animal; Drug Carriers; | 1996 |
Apparent exacerbation of vitiligo syndrome in a patient with pulmonary Mycobacterium avium complex disease who received clofazimine therapy.
Topics: Aged; Clofazimine; Female; Humans; Mycobacterium avium Complex; Mycobacterium avium-intracellulare I | 1996 |
The management of mycobacterial infections in HIV seropositive individuals. Jefferiss Wing Therapeutics and Protocols Group.
Topics: Adrenal Cortex Hormones; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitu | 1996 |
Therapeutic efficacy of liposomal clofazimine against Mycobacterium avium complex in mice depends on size of initial inoculum and duration of infection.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Chronic Disease; Clofazimine; Disease Models, Animal; | 1997 |
Enhancement of antibacterial activity of clofazimine against Mycobacterium avium-Mycobacterium intracellulare complex infection induced by IFN-gamma is mediated by TNF-alpha.
Topics: Animals; Anti-Bacterial Agents; Clofazimine; Female; Interferon-gamma; Liposomes; Macrophages; Male; | 1997 |
Pulmonary clofazimine crystals in two patients with the acquired immunodeficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Bacteremia; Bronchoalveolar Lav | 1997 |
Clofazimine crystals in the cytoplasm of pulmonary macrophages.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bronchoalveolar Lavage; Clofazimine; Crystallization; Drug | 1999 |
Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection.
Topics: Animals; Anti-Bacterial Agents; Clofazimine; Disease Models, Animal; Drug Carriers; Female; Freeze D | 2000 |
Advances in prevention and treatment of MAC.
Topics: AIDS-Related Opportunistic Infections; Azithromycin; CD4 Lymphocyte Count; Clarithromycin; Clinical | 1995 |
Macrolides, azalides, and streptogrammins.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; B | 1996 |
Progress report: prophylaxis and therapy for MAC.
Topics: Acquired Immunodeficiency Syndrome; Antitubercular Agents; Azithromycin; Clarithromycin; Clofazimine | 1996 |
Pot shots.
Topics: Acetylcysteine; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antitubercula | 1996 |
MAC management.
Topics: Acquired Immunodeficiency Syndrome; Amikacin; Antitubercular Agents; Ciprofloxacin; Clarithromycin; | 1996 |
In-vivo activity of streptomycin and clofazimine against established infections of Mycobacterium avium complex in beige mice.
Topics: Animals; Clofazimine; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Ma | 1992 |
In vitro, in vivo, and intracellular chemotherapeutic activity of B746, a clofazimine analogue against Mycobacterium avium complex.
Topics: Animals; Clofazimine; Dose-Response Relationship, Drug; Drug Therapy, Combination; In Vitro Techniqu | 1992 |
Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy.
Topics: Acquired Immunodeficiency Syndrome; Anti-Bacterial Agents; Antibiotics, Antitubercular; Ciprofloxaci | 1991 |
Successful treatment of acquired immunodeficiency syndrome-related Mycobacterium avium complex disease with a multiple drug regimen including amikacin.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amikacin; Antitubercular Agents; Ciprofloxacin; Clofazimi | 1991 |
Quadruple-drug therapy for Mycobacterium avium-intracellulare bacteremia in AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Infective Agents; Clofazimine; Drug Therapy, Combina | 1990 |
Clofazamine-induced generalized retinal degeneration.
Topics: Acquired Immunodeficiency Syndrome; Adult; Clofazimine; Dark Adaptation; Electroretinography; Fluore | 1990 |
Activity of rifabutin alone and in combination with clofazimine, kanamycin and ethambutol against Mycobacterium intracellulare infections in mice.
Topics: Animals; Antitubercular Agents; Clofazimine; Drug Therapy, Combination; Ethambutol; Female; Kanamyci | 1989 |
Effect of combined therapy with ansamycin, clofazimine, ethambutol, and isoniazid for Mycobacterium avium infection in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Anti-Bacterial Agents; Antitubercular Agen | 1989 |
Pulmonary clofazimine crystals in a child with acquired immunodeficiency syndrome and disseminated Mycobacterium avium-intracellulare infection.
Topics: Acquired Immunodeficiency Syndrome; Child; Clofazimine; Crystallization; Humans; Lung; Male; Mycobac | 1988 |